N6-(4-chlorobenzyl)-N4-(5-methyl-1H-pyrazol-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine

ID: ALA5201909

PubChem CID: 168291822

Max Phase: Preclinical

Molecular Formula: C21H23ClN8O

Molecular Weight: 438.92

Names and Identifiers

Canonical SMILES:  Cc1cc(Nc2nc(NCc3ccc(Cl)cc3)nc3c2cnn3C2CCOCC2)n[nH]1

Standard InChI:  InChI=1S/C21H23ClN8O/c1-13-10-18(29-28-13)25-19-17-12-24-30(16-6-8-31-9-7-16)20(17)27-21(26-19)23-11-14-2-4-15(22)5-3-14/h2-5,10,12,16H,6-9,11H2,1H3,(H3,23,25,26,27,28,29)

Standard InChI Key:  OYXQGIWYGDOFOS-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 31 35  0  0  0  0  0  0  0  0999 V2000
   -1.7906    0.4637    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0761    0.8760    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3642    0.4641    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3642   -0.3610    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0742   -0.7728    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7906   -0.3647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5981   -0.6159    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.0707    0.0403    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5767    0.7106    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3504   -0.7736    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0650   -0.3610    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7796   -0.7736    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4944   -0.3612    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2066   -0.7732    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2066   -1.5986    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4962   -2.0106    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7796   -1.6023    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0761    1.7012    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7907    2.1138    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5053    1.7012    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1241    2.2725    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7933    3.0070    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9692    2.9147    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9211    2.0590    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8116   -1.4130    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2282   -1.9964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4417   -2.7935    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2388   -3.0070    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -3.8223   -2.4235    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6087   -1.6265    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9211   -2.0113    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  6  5  2  0
  1  6  1  0
  6  7  1  0
  7  8  1  0
  9  8  2  0
  1  9  1  0
  4 10  1  0
 10 11  1  0
 11 12  1  0
 13 12  2  0
 14 13  1  0
 15 14  2  0
 16 15  1  0
 17 16  2  0
 12 17  1  0
  2 18  1  0
 18 19  1  0
 20 19  1  0
 20 21  2  0
 21 22  1  0
 23 22  1  0
 19 23  2  0
 21 24  1  0
 25  7  1  0
 25 26  1  0
 27 26  1  0
 28 27  1  0
 29 28  1  0
 25 30  1  0
 30 29  1  0
 15 31  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5201909

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 438.92

Molecular Weight (Monoisotopic): 438.1683

AlogP: 4.22

#Rotatable Bonds: 6

Polar Surface Area: 105.57

Molecular Species: NEUTRAL

HBA: 8

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 9

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 12.27

CX Basic pKa: 3.23

CX LogP: 3.44

CX LogD: 3.44

Aromatic Rings: 4

Heavy Atoms: 31

QED Weighted: 0.41

Np Likeness Score: -1.80

References

1. Sun Y, Sun Y, Wang L, Wu T, Yin W, Wang J, Xue Y, Qin Q, Sun Y, Yang H, Zhao D, Cheng M..  (2022)  Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer.,  238  [PMID:35576702] [10.1016/j.ejmech.2022.114424]

Source

Source(1):

• Scientific Literature